Second Quebec Hospital Adopts Steriwave
19 June 2025
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Second Quebec Hospital Adopts Steriwave
Hôtel-Dieu de Sherbrooke Becomes Second Hospital in Quebec to Adopt Ondine's Steriwave® Photodisinfection as Standard of Care for Orthopedic Surgeries
Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Hôtel-Dieu de Sherbrooke has adopted Steriwave® nasal photodisinfection as standard of care for its orthopedic surgeries. This makes Hôtel-Dieu the second hospital in Quebec to formally adopt this innovative infection prevention technology into its routine surgical protocols. Steriwave is now in six of Canada's top ten largest hospitals.
The Hôtel-Dieu implementation follows the successful deployment of Steriwave at Hôpital Fleurimont (CIUSSS de l'Estrie - CHUS), the first in Quebec to use Steriwave for high-risk neuro and spine surgery patients. Under the leadership of Dr. Bernard LaRue and his clinical research team, Fleurimont reported a 78.8% reduction in surgical site infections (SSIs) among patients receiving pre-operative Steriwave therapy. These compelling results, presented at the 25th Annual Scientific Conference of the Canadian Spine Society in February 2025, highlight Steriwave's efficacy, safety, and ease of integration into preoperative workflows. In addition to those results in Quebec, Mid Yorkshire Teaching NHS Trust in the UK reported a 71% reduction in joint surgery infections following the adoption of Steriwave protocols.
With the adoption of Steriwave by Hôtel-Dieu, the Estrie region of Quebec continues to demonstrate leadership in infection control. The hospital joins a growing number of healthcare institutions in Canada and in other countries implementing Steriwave as part of their strategies to reduce SSIs and enhance patient outcomes. Steriwave's rapid, full-spectrum nasal decolonization provides superior protection without contributing to antimicrobial resistance or requiring patient compliance.
SSIs remain a major healthcare challenge. Approximately 69% of SSIs are caused by pathogens that colonize the nasal passages,[1-3] highlighting the nose as a critical reservoir for infection-causing microbes. This underscores the importance of effective pre-surgical nasal decolonization strategies. At the same time, there is increasing need for technologies that do not rely on patient compliance-particularly given the variability of topical antibiotic use and growing antimicrobial resistance.
Carolyn Cross, CEO of Ondine Biomedical, stated:
"We are proud to support Hôtel-Dieu de Sherbrooke as the second Quebec hospital to adopt nasal photodisinfection as standard of care. In today's healthcare environment, where antibiotic resistance is a mounting threat, adopting innovative and proven infection prevention strategies is more important than ever. We commend the hospital's leadership and dedication to patient safety."
Steriwave is a painless non-antibiotic antimicrobial therapy that destroys harmful pathogens in the nose without promoting resistance or relying on patient compliance. The treatment involves applying a proprietary photosensitive agent to each nostril followed by illumination with a specific wavelength of red light. The process takes only minutes and destroys bacteria, viruses, and fungi, including drug-resistant organisms, in the nasal cavity.
Steriwave is approved in Canada, Europe (CE mark), Australia, Mexico, and several other countries for use in nasal decolonization. In the United States, Steriwave has been granted Qualified Infectious Disease Product (QIDP) designation and Fast Track status by the U.S. FDA and is currently undergoing clinical trials to support regulatory approval.
Enquiries:
|
Ondine Biomedical Inc. |
www.ondinebio.com |
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
Strand Hanson Limited (Nominated & Financial Adviser) |
|
|
James Harris, Richard Johnson |
+44 (0)20 7409 3494 |
|
|
|
|
RBC Capital Markets (Broker) |
|
|
Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy |
+44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund